1 Research grants; 2 Consulting fees; 3 Employee; 4 Speakers bureau; 5 Stocks, stock options, or bond holdings.

Size: px
Start display at page:

Download "1 Research grants; 2 Consulting fees; 3 Employee; 4 Speakers bureau; 5 Stocks, stock options, or bond holdings."

Transcription

1 Screening & Randomization 11/7/ Disclosures: This study was funded by Roche Efficacy and Safety of Tocilizumab in Patients With Systemic Juvenile Idiopathic Arthritis: 2-Year Data From a Phase III Clinical Trial F. De Benedetti, H Brunner, N. Ruperto, A Kenwright, C. Devlin, I. Calvo, R. Cuttica, A. Ravelli, R Schneider, D. Eleftheriou, C. Wouters, R. Xavier, L. Zemel, E. Baildam, R. Burgos-Vargas, P. Dolezalova, S. M. Garay, R. Joos, A. Grom, N. Wulffraat, Z. Zuber, F. Zulian,. A. Martini, D. Lovell The authors disclose the following financial relationships: F. De Benedetti (All funds go to the children Hospital): Abbott, 1 BMS, 1,2 Pfizer, 1,2 SOBI, 1 Novimmune, 1 Roche, 1,2 Novartis 1 H. Brunner (all funds go to Cincinnati Children s Hospital): Amgen, 2 Bristol-Meyers Squibb, 1 Abbott, 1 Pfizer, 2 Roche, 2 Novartis, 2 UBC 2 N. Ruperto (all funds go to Gaslini Children s Hospital): BMS, 1,4 Abbott, 1 Novartis, 1 Roche, 1,4 Centocor, 1 ACRAF, 1 Pfizer, 1 Xoma 1 A. Kenwright: Roche,4 C. Devlin: Roche,4 I. Calvo: None R. Cuttica: None A. Ravelli: None R. Schneider: Roche, 2 Innomar Strategies 2 D. Eleftheriou: None C Wouters: GSK 1 R. Xavier: Roche, 1,2,4 Pfizer, 1,2,4 Janssen 2,4 L. Zemel: None E. Baildam: None R. Burgos-Vargas: Abbot, 2, BMS, 2, MSD, 2, Pfizer, 2, Roche 1,2, P. Dolezalova: None S. M. Garay: None R. Joos: None A. Grom: Novartis 2 N. Wulffraat: None Z. Zuber: None F. Zulian: None A. Martini (all funds go to Gaslini Children s Hospital): BMS, 1,4 Abbott, 1 Novartis, 1,2 Roche, 1,2 Centocor, 1 ACRAF, 1 Pfizer, 1 Xoma 1 D. Lovell (all funds go to Cincinnati Children s Hospital): Astra-Zeneca, 2 Wyeth, 2 Amgen, 2 BMS, 1 Abbott, 1 Pfizer, 2 Regneron, 2 Roche, 2 Novartis, 2 UBC, 2 Xoma 2 1 Research grants; 2 Consulting fees; Employee; 4 Speakers bureau; Stocks, stock options, or bond holdings. Evidence-Based Medicine (EBM) TENDER: 12-Week Randomized, Double-Blind, Placebo- Controlled, Parallel-Group, 2-Arm Study (Part I) with Single- Arm, Open-label Extension (Parts II and III) Years in Total 4 Woo P, Wilkinson N, Prieur AM, et al. Open-label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res Ther. 2;7:R1281-R1288. Yokota S, Imagawa T, Mori M, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 28;71: De Benedetti F, Brunner H, Ruperto N, et al. Efficacy and safety of tocilizumab (TCZ) in patients (pts) with systemic juvenile idiopathic arthritis (sjia): TENDER 2-week data. Presented at EULAR 211. Ann Rheum Dis 211;7(Suppl):67 Study Design Double-Blind Period (Part I) 7 pts 7 pts TCZ 8 or 12 mg/kg a x 6 Placebo x Week Day Escape with rescue therapy Open-Label Period (Parts II - III) TCZ 8 or 12 mg/kg a every 2 weeks for 92 weeks (subsequent -year extension added) a 8 mg/kg if body weight kg; 12 mg/kg if body weight < kg. TENDER: Key Inclusion Criteria TENDER: Demographic and Baseline Characteristics 6 Diagnosis of sjia according to ILAR criteria Age 2 17 years Persistent disease activity for 6 months, with an inadequate response to corticosteroids and NSAIDs due to toxicity or lack of efficacy active joints OR 2 active joints with fever >8 C Maximum dose of oral corticosteroids:. mg/kg/day (prednisone equivalent) Stable dose of oral corticosteroids, MTX, and/or NSAIDs No other DMARDs or biologic allowed N = 112 Age (y), mean (SD) 9.7 (4.6) Disease duration (y), mean (SD).2 (4.1) Previous DMARDs use, n (%) 82 (7) Previous TNF inhibitor use, n (%) 81 (72) Previous IL-1 inhibitor use, n (%) 4 (48) Physician VAS, mean (SD) 64.9 (22.) Parent/patient VAS, mean (SD) 8.7 (24.4) Number of active joints, mean (SD) 19.8 (1.7) Number of joints with LOM, mean (SD) 19.8 (1.6) ESR (mm/h) mean (SD) 7.6 (4.2) CHAQ-DI, mean (SD) 1.7 (.9) CRP (mg/l), mean (SD) (49.24) Fever (last 7 days), n (%) 48 (4) Background oral corticosteroid dose, (mg/kg/day PDN eq), mean (SD). (.2) Re-baselined at the first dose of TCZ. 1

2 Double-blind Baseline to Week 12 Open-label Mean (SE) CHAQ-DI 11/7/211 TENDER: Efficacy in Double-Blind Phase JIA ACR + Absence of Fever at Week 12 JIA ACR /7/9 Responses at Week 12 7 TENDER Patient Disposition Placebo n=7 Screened N=126 Enrolled N=112 Tocilizumab n= % (9% CI: )*, Placebo (n=7) n=9 n= Placebo TCZ TCZ (n=7) JIA JIA JIA (n=7) (n=7) ACR ACR7 ACR9 *Weighted difference. p<.1 Cochran-Mantel-Haenszel analysis adjusted for randomization stratification factors applied at baseline TCZ (n=7) Completed Escaped Completed Escaped a Withdrew 17 (46%) 2 (4%) 72 (96%) 2 (%) Fever AE 1 (27%) JIA ACR Refused Tx Flare 9 (24%) Other c 1 (%) AE Enrolled in Open-Label Extension Phase N=11 Death Withdrew 18 Response Ongoing N=92 Other b a 1 patient in the TCZ group received escape therapy on study day 1; the investigator initially suspected MAS, which was later determined to be liver function test elevations. b patients refused treatment, and 1 patient did not return. c Patient was initially suspected to have MAS, which was later determined to be an sjia flare. TENDER: Analyses of 14-Week Data Baseline Patients randomized to TCZ day 1 Patients randomized to placebo were re-baselined at the first TCZ dose Endpoints Durability and magnitude of TCZ efficacy response Effect of TCZ to reduce or eliminate oral corticosteroids Safety of TCZ in chronic administration Analysis population 61 patients received at least 14 weeks of TCZ treatment Patients who withdrew because of insufficient therapeutic response before week 14 were included and considered nonresponders (n=) for JIA ACR responses Patients who withdrew for nonefficacy-related reasons were excluded (n=1 [9 safety and 6 other]) for JIA ACR responses 9 JIA ACR Responses Over Time JIA ACR JIA ACR JIA ACR JIA ACR9 n = Percentage is based on number of patients who reached time point + patients who withdrew because of insufficient therapeutic response and are assumed to have been nonresponders. 1 No Active Joints and Inactive Disease Over Time No Active Joints Inactive Disease Physical Function Over Time No Joints with limitation CHAQ-DI score b of movement a. 2. CHAQ-DI >.7 Baseline: 82.1% 2. Week 14: 4.7% a Patients who withdrew because of insufficient therapeutic response are assumed to be nonresponders. b Patients who withdrew are excluded. 12 2

3 Mean (SE) Dose 11/7/211 Mean Oral Corticosteroid Dose Over Time 1 Cumulative Safety % discontinued CS by week 14 Mean dose decreased to.4 mg/kg/day Patients who withdrew have been excluded at postwithdrawal visits.. Prior Safety Update a Week 14 b Exposure to TCZ, y Rate of SAEs/1PY (n) 24.8 (9) 2. (47) Rate of infections/1py (n).6 (4) (7) Rate of serious infection AEs/1PY (n) 11.4 (18) 1.9 (22) SAEs related (remotely, possibly, probably) to TCZ/1 PY (n) 8. (1) 7.4 (1) Macrophage activation syndrome/1py (n) 1.9 () 1. () AEs leading to withdrawal/1py (n).8 (6) c. (6) c Deaths/1PY (n).6 (1) 1. () Pneumothorax 1 1 Sepsis (possibly related) 1 Road Traffic Accident 1 a Includes all safety data in the database up to and including August 1, 21. b Includes all safety data in the database up to the week 14 infusion (based on date of randomization) for each pt. The last date for this was May 1, 211. c Includes 2 withdrawals because of transaminase increases that were protocol mandated. 16 Deaths after discontinuation from TENDER Pat # Country 11* Netherlands 1611 Italy Event name Death of unknown cause Age at death 1 y mo. Atrioventricular 17 y block (in 9 mo. hyperkalaemia) 164 Italy Cardiac arrest 18 y 7 mo. Date of Death (duration from last TCZ dose) July-1 (6 mo.) Dec-11-1 (1 y 1 mo.) Duration of TCZ tx Date of last TCZ dose wks Jan-21-1 Reason for withdrawal from TENDER therapeutic response AE - Pulmonary 4 wks Nov-18-9 venoocclusive disease Apr-1-11 (1 y 2 mo.) 48 wks Feb-1-1 therapeutic response Most Common* Serious Adverse Events Event, n (%) N = 112 Varicella 4 (.6) Gastroenteritis 4 (.6) Macrophage activation syndrome (2.7) Pneumonia (2.7) Dehydration 2 (1.8) Herpes zoster 2 (1.8) * Patient 11 entered another biologic study April 21. *Preferred terms with incidence > 1 patient 18 TENDER: Clinical Laboratory Evaluations Grade a No. (%) Neutrophils (-<1, cells/mm ) 26 (2.2) 4 (< cells/mm ) 2 (1.8) b Platelets (2,-<, cells/mm ) 1 (.9) c 4 (<2, cells/mm ) ALT (>-2 x ULN) 9 (8.) 4 (>2 x ULN) 1 (.9) c Conclusions TENDER 2-year results demonstrated sustained efficacy and no change in the safety profile during long-term TCZ treatment Responses occurred early and were maintained over time 6% of patients who received 14 weeks of TCZ were able to discontinue oral corticosteroids 7% in inactive disease status by week 14 a Common Toxicity Criteria Vers. Grades. b Both single occurrences, returned to normal no associated infection. c Platelet decrease and ALT increase occurred during MAS.

4 11/7/ Argentina Cuttica Espada Garay Australia Allen Chaitow Murray Belgium Joos Wouters Brazil Silva Xavier Canada Roth Schneider Czech Republic Dolezalova Germany Horneff Huppertz Minden Greece Mantzourani Siammopoulou Vougiouka Italy Cortis Gerloni Martini Zulian Mexico Burgos Maldonado Netherlands Norway Poland Slovakia Wulffraat Flato Zuber Rovensky Spain Calvo Garcia Consuegra UK Baildam Woo USA Investigators 4 centers from 17 countries Brown Chalom Jerath Kimura Lovell Myones O'Neill Onel Spalding Zemel Back-up Infections N = 112 Infections and infestations/1 PY (7) Serious infection AEs/1 PY (n) 1.9 (22) Infections (remotely, possibly, probably) related to study treatment 8 Gastroenteritis 1 Otitis media 1 Pharyngotonsillitis 1 Septic arthritis 1 Streptococcal sepsis 1 Tonsillitis 1 Upper respiratory infection 1 Varicella 1 TENDER: Oral Corticosteroid Tapering Allowed if ESR <2 mm/hr and In double-blind phase at weeks 6 and 8 (not at week 1) If absence of fever and JIA ACR7 In open-label extension phase (not at weeks 24,, 76, and 12) If absence of fever and JIA ACR Not permitted more frequently than every 2 weeks Maximum tapering allowed: 2% of current (last visit) dose in double-blind phase and at investigator s discretion in open-label JIA ACR Responses Over Time JIA ACR and absence of fever JIA ACR 2 JIA ACR JIA ACR7 JIA ACR n = Percentage is based on number of patients who reached time point + patients who withdrew because 2 No Active Joints and No Joints With Limitation Of Movement Over Time No Active Joints No Joints with limitation of movement n =

5 Mean (SE) Number of Active Joints 11/7/211 Physician Global Assessment VAS 1 mm 1 2 Patient/Parent Global Assessment VAS 1 mm n = n = Active Joint Count Over Time n = Percentage is based on number of patients who reached time point + patients who withdrew are excluded.

11/11/2012. Disclosures. Systemic Juvenile Idiopathic Arthritis Growth Defect. Chronic Inflammation and Stunted Growth

11/11/2012. Disclosures. Systemic Juvenile Idiopathic Arthritis Growth Defect. Chronic Inflammation and Stunted Growth // Catch-up Growth During Tocilizumab Therapy for Systemic Juvenile Idiopathic Arthritis: -Year Data From a Phase 3 Clinical Trial Fabrizio De Benedetti, Nicolino Ruperto, Graciela Espada, Valeria Gerloni,

More information

Supplementary Appendix

Supplementary Appendix Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: De Benedetti F, Brunner HI, Ruperto N, et al. Randomized trial

More information

New Evidence reports on presentations given at EULAR Tocilizumab for the Treatment of Rheumatoid Arthritis and Juvenile Idiopathic Arthritis

New Evidence reports on presentations given at EULAR Tocilizumab for the Treatment of Rheumatoid Arthritis and Juvenile Idiopathic Arthritis New Evidence reports on presentations given at EULAR 2011 Tocilizumab for the Treatment of Rheumatoid Arthritis and Juvenile Idiopathic Arthritis Report on EULAR 2011 presentations Benefit of continuing

More information

11/7/2011. Disclosures

11/7/2011. Disclosures 11/7/11 Efficacy & Safety of, a Fully Human Selective Anti-IL-1β Antibody, In Active Systemic Juvenile Idiopathic Arthritis Results From Two Phase III Studies Disclosures This study was sponsored by Novartis

More information

Efficacy and Safety of Tocilizumab in the Treatment of Rheumatoid Arthritis and Juvenile Idiopathic Arthritis

Efficacy and Safety of Tocilizumab in the Treatment of Rheumatoid Arthritis and Juvenile Idiopathic Arthritis New Evidence reports on presentations given at EULAR 2010 Efficacy and Safety of Tocilizumab in the Treatment of Rheumatoid Arthritis and Juvenile Idiopathic Arthritis Report on EULAR 2010 presentations

More information

Charité - University Hospital, Free University and Humboldt University of Berlin, Berlin, Germany; 2 Sanofi Genzyme, Bridgewater, NJ, USA; 3

Charité - University Hospital, Free University and Humboldt University of Berlin, Berlin, Germany; 2 Sanofi Genzyme, Bridgewater, NJ, USA; 3 Efficacy and Safety of Sarilumab Versus Adalimumab in a Phase 3, Randomized, Double-blind, Monotherapy Study in Patients With Active Rheumatoid Arthritis With Intolerance or Inadequate Response to Methotrexate

More information

Annual Rheumatology & Therapeutics Review for Organizations & Societies

Annual Rheumatology & Therapeutics Review for Organizations & Societies Annual Rheumatology & Therapeutics Review for Organizations & Societies Comparative Effectiveness Studies of Biologics Learning Objectives Understand the motivation for comparative effectiveness research

More information

New Evidence reports on presentations given at EULAR Safety and Efficacy of Tocilizumab as Monotherapy and in Combination with Methotrexate

New Evidence reports on presentations given at EULAR Safety and Efficacy of Tocilizumab as Monotherapy and in Combination with Methotrexate New Evidence reports on presentations given at EULAR 2009 Safety and Efficacy of Tocilizumab as Monotherapy and in Combination with Methotrexate Report on EULAR 2009 presentations Tocilizumab inhibits

More information

Keywords Biologicals. Juvenile idiopathic arthritis. Tocilizumab. Treatment ORIGINAL ARTICLE

Keywords Biologicals. Juvenile idiopathic arthritis. Tocilizumab. Treatment ORIGINAL ARTICLE Clinical Rheumatology (2018) 37:1807 1816 https://doi.org/10.1007/s10067-018-4071-9 ORIGINAL ARTICLE Long-term, interventional, open-label extension study evaluating the safety of tocilizumab treatment

More information

The Hospital for Sick Children Technology Assessment at SickKids (TASK)

The Hospital for Sick Children Technology Assessment at SickKids (TASK) The Hospital for Sick Children Technology Assessment at SickKids (TASK) THE USE OF BIOLOGIC RESPONSE MODIFIERS IN POLYARTICULAR-COURSE JUVENILE IDIOPATHIC ARTHRITIS Report No. 2010-01 Date: January 11,

More information

University of California, San Diego, School of Medicine, La Jolla, CA, USA; 2

University of California, San Diego, School of Medicine, La Jolla, CA, USA; 2 2194 Long-term (104-Week) Efficacy and Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients With Psoriatic Arthritis: Results From a Phase III, Randomized, Controlled Trial

More information

10/28/2013. Disclosures. Objectives. Background. Study Design. Key Inclusion Criteria

10/28/2013. Disclosures. Objectives. Background. Study Design. Key Inclusion Criteria Randomization (1:1:1:1) /28/13 Tocilizumab in Combination Therapy and Monotherapy Versus Methotrexate in Methotrexate-Naive Patients With Early Rheumatoid Arthritis: Clinical and Radiographic Outcomes

More information

SYNOPSIS. Clinical Study Report IM Double-blind Period

SYNOPSIS. Clinical Study Report IM Double-blind Period Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Abatacept () Name of Active Ingredient: Abatacept () Individual Study Table Referring to the Dossier SYNOPSIS (For National Authority

More information

2.0 Synopsis. Adalimumab M Clinical Study Report Final R&D/15/1093. (For National Authority Use Only)

2.0 Synopsis. Adalimumab M Clinical Study Report Final R&D/15/1093. (For National Authority Use Only) 2.0 Synopsis AbbVie Inc. Name of Study Drug: Adalimumab Name of Active Ingredient: Adalimumab Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority Use Only) Title

More information

Synopsis (C0524T12 GO LIVE)

Synopsis (C0524T12 GO LIVE) Protocol: EudraCT No.: 2005-003232-21 Title of the study: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFα Monoclonal Antibody, Administered Intravenously,

More information

Horizon Scanning Technology Summary. Abatacept (Orencia) for juvenile idiopathic arthritis. National Horizon Scanning Centre.

Horizon Scanning Technology Summary. Abatacept (Orencia) for juvenile idiopathic arthritis. National Horizon Scanning Centre. Horizon Scanning Technology Summary National Horizon Scanning Centre Abatacept (Orencia) for juvenile idiopathic arthritis June 2007 This technology summary is based on information available at the time

More information

Adalimumab M Clinical Study Report Final R&D/14/1263. Page:

Adalimumab M Clinical Study Report Final R&D/14/1263. Page: Synopsis AbbVie Inc. Name of Study Drug: Adalimumab Name of Active Ingredient: Adalimumab Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority Use Only) Title of Study:

More information

Guideline Update: 2013 ACR Recommendations Norman T. Ilowite, MD

Guideline Update: 2013 ACR Recommendations Norman T. Ilowite, MD Guideline Update: 2013 ACR Recommendations Norman T. Ilowite, MD Professor of Pediatrics Albert Einstein College of Medicine Bronx, NY Introduction Recommendations always intended to be reviewed annually

More information

Study synopsis of the global non-interventional study SWITCH-RA

Study synopsis of the global non-interventional study SWITCH-RA Study synopsis of the global non-interventional study SWITCH-RA Protocol number: MA22401 Title of Study: A global multi-centre observational study in RA patients who are non-responders or intolerant to

More information

RoACTEMRA for Systemic Juvenile Idiopathic Arthritis (sjia)

RoACTEMRA for Systemic Juvenile Idiopathic Arthritis (sjia) RoACTEMRA for Systemic Juvenile Idiopathic Arthritis (sjia) HEALTHCARE PROFESSIONAL BROCHURE IMPORTANT EFFICACY AND SAFETY INFORMATION To assist healthcare professionals in assessing the benefits and risks

More information

Management of patients on tocilizumab in daily practic. Evidence Based Medicine Official recommendations Expert opinion

Management of patients on tocilizumab in daily practic. Evidence Based Medicine Official recommendations Expert opinion S90 Tables Evidence Based Medicine Official recommendations Expert opinion Table 1: Examples of drugs that are metabolized by the cytochrome P450 isoenzymes The full list is available online at http://medicine.iupui.edu/clinpharm/ddis.

More information

Clinical pharmacology of tocilizumab for the treatment of systemic juvenile idiopathic arthritis

Clinical pharmacology of tocilizumab for the treatment of systemic juvenile idiopathic arthritis For reprint orders, please contact reprints@expert-reviews.com Clinical pharmacology of tocilizumab for the treatment of systemic juvenile idiopathic arthritis Expert Rev. Clin. Pharmacol. 6(2), 123 137

More information

Full Novartis CTRD Results Template

Full Novartis CTRD Results Template Full Novartis CTRD Results Template Sponsor Novartis Generic Drug Name vildagliptin Therapeutic Area of Trial Type 2 diabetes Approved Indication Type 2 diabetes Protocol Number CLAF237A23137E1 Title A

More information

Individual Study Table Referring to Part of Dossier: Use Only) Name of Study Drug:

Individual Study Table Referring to Part of Dossier: Use Only) Name of Study Drug: 2.0 Synopsis AbbVie Inc. Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: Volume: Adalimumab (Humira ) Page: Name of Active Ingredient: Adalimumab

More information

Abatacept (Orencia) for active rheumatoid arthritis. August 2009

Abatacept (Orencia) for active rheumatoid arthritis. August 2009 Abatacept (Orencia) for active rheumatoid arthritis August 2009 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to

More information

Technology appraisal guidance Published: 14 December 2011 nice.org.uk/guidance/ta238

Technology appraisal guidance Published: 14 December 2011 nice.org.uk/guidance/ta238 Tocilizumab for the treatment of systemic juvenile idiopathic arthritis Technology appraisal guidance Published: 14 December 2011 nice.org.uk/guidance/ta238 NICE 2018. All rights reserved. Subject to Notice

More information

Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC

Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC Update on the Treatment of Rheumatoid Arthritis Sabrina Fallavollita MDCM McGill University Canadian Society of Internal Medicine

More information

Extended report. Colorado, USA; 2 Pontificial Catholic University, School of Medicine, Porto Alegre, Brazil; Oklahoma City, Oklahoma, USA;

Extended report. Colorado, USA; 2 Pontificial Catholic University, School of Medicine, Porto Alegre, Brazil; Oklahoma City, Oklahoma, USA; 1 Denver Arthritis Clinic, Denver, Colorado, USA; 2 Pontificial Catholic University, School of Medicine, Porto Alegre, Brazil; 3 Health Research of Oklahoma, Oklahoma City, Oklahoma, USA; 4 Arthritis &

More information

New Evidence reports on presentations given at EULAR Tocilizumab for the Treatment of Rheumatoid Arthritis

New Evidence reports on presentations given at EULAR Tocilizumab for the Treatment of Rheumatoid Arthritis New Evidence reports on presentations given at EULAR 2012 Tocilizumab for the Treatment of Rheumatoid Arthritis Report on EULAR 2012 presentations Tocilizumab monotherapy is superior to adalimumab monotherapy

More information

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Rheumatology journal club October 20, 2017 Presented by: Matthew Stoll MD,PhD,PSCS

Rheumatology journal club October 20, 2017 Presented by: Matthew Stoll MD,PhD,PSCS Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis (Mease et al., 2017) Rheumatology journal club October 20,

More information

Pharmacy Medical Necessity Guidelines: Actemra (tocilizumab)

Pharmacy Medical Necessity Guidelines: Actemra (tocilizumab) Pharmacy Medical Necessity Guidelines: Effective: July 11, 2017 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review SQ: RXUM/ RX / Pharmacy (RX) or Medical

More information

Kenneth W. Mahaffey, MD and Keith AA Fox, MB ChB

Kenneth W. Mahaffey, MD and Keith AA Fox, MB ChB Once-daily oral direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation Kenneth W. Mahaffey, MD and Keith AA Fox, MB ChB on behalf

More information

ACTEMRA Risk Mitigation Strategy Presenter Name, Degree

ACTEMRA Risk Mitigation Strategy Presenter Name, Degree ACTEMRA Risk Mitigation Strategy Presenter Name, Degree Medical Science Liaison Genentech, Inc. 1 Indications and Dosage Rheumatoid Arthritis (RA) (1 of 2) Indication in RA ACTEMRA (tocilizumab) is indicated

More information

Synopsis (C0743T10) CNTO 1275 Module 5.3 C0743T10. Associated with Module 5.3 of the Dossier

Synopsis (C0743T10) CNTO 1275 Module 5.3 C0743T10. Associated with Module 5.3 of the Dossier Module 5.3 Protocol: EudraCT No.: 2005-003525-92 Title of the study: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of, a Fully Human Anti-IL-12 Monoclonal Antibody, Administered

More information

Adalimumab with or without Methotrexate in Juvenile Rheumatoid Arthritis

Adalimumab with or without Methotrexate in Juvenile Rheumatoid Arthritis The new england journal of medicine original article Adalimumab with or without Methotrexate in Juvenile Rheumatoid Arthritis Daniel J. Lovell, M.D., M.P.H., Nicolino Ruperto, M.D., M.P.H., Steven Goodman,

More information

Tocilizumab for the treatment of systemic juvenile idiopathic arthritis

Tocilizumab for the treatment of systemic juvenile idiopathic arthritis in collaboration with: Tocilizumab for the treatment of systemic juvenile idiopathic arthritis Produced by Authors Correspondence to Kleijnen Systematic Reviews Ltd. in collaboration with Erasmus University

More information

Technology appraisal guidance Published: 16 December 2015 nice.org.uk/guidance/ta373

Technology appraisal guidance Published: 16 December 2015 nice.org.uk/guidance/ta373 Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis Technology appraisal guidance Published: 16 December 2015 nice.org.uk/guidance/ta373 NICE 2017. All rights reserved.

More information

Primary Endpoint The primary endpoint is overall survival, measured as the time in weeks from randomization to date of death due to any cause.

Primary Endpoint The primary endpoint is overall survival, measured as the time in weeks from randomization to date of death due to any cause. CASE STUDY Randomized, Double-Blind, Phase III Trial of NES-822 plus AMO-1002 vs. AMO-1002 alone as first-line therapy in patients with advanced pancreatic cancer This is a multicenter, randomized Phase

More information

Individual Study Table Referring to Part of Dossier: Volume: Page:

Individual Study Table Referring to Part of Dossier: Volume: Page: 2.0 Synopsis Abbott Laboratories Eisai Co., Ltd Name of Study Drug: Humira 40 mg/ 0.8 ml (To be determined for 20 mg product) Humira 20 mg/ 0.4 ml (To be determined for 20 mg product) Name of Active Ingredient:

More information

Title: Predictive factors of relapse, in patients with JIA in remission, after discontinuation of synthetic disease-modifying antirheumatic drugs.

Title: Predictive factors of relapse, in patients with JIA in remission, after discontinuation of synthetic disease-modifying antirheumatic drugs. Title: Predictive factors of relapse, in patients with JIA in remission, after discontinuation of synthetic disease-modifying antirheumatic drugs. Background Juvenile idiopathic arthritis (JIA) is not

More information

Extended report. Colorado, USA; 2 Pontificial Catholic University, School of Medicine, Porto Alegre, Brazil; Oklahoma City, Oklahoma, USA;

Extended report. Colorado, USA; 2 Pontificial Catholic University, School of Medicine, Porto Alegre, Brazil; Oklahoma City, Oklahoma, USA; Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate

More information

golimumab Principal Investigator(s): Principal Investigator: Michael E. Weinblatt, MD Brigham and Women s

golimumab Principal Investigator(s): Principal Investigator: Michael E. Weinblatt, MD Brigham and Women s Module 5.3.5.1 Rheumatoid Arthritis IV (24-Week submission) 24-Week CNTO148ART3001Clinical Study Report SYNOPSIS Issue Date: 07 Nov 2011 Document No.: EDMS-ERI-22836553 Name of Sponsor/Company Name of

More information

Efficacy and Safety of Rituximab in the Treatment of Rheumatoid Arthritis and ANCA-associated Vasculitis

Efficacy and Safety of Rituximab in the Treatment of Rheumatoid Arthritis and ANCA-associated Vasculitis New Evidence reports on presentations given at ACR/ARHP 2010 Efficacy and Safety of Rituximab in the Treatment of Rheumatoid Arthritis and ANCA-associated Vasculitis Report on ACR/ARHP 2010 presentations

More information

BRIEFING DOCUMENT. human, recombinant fusion protein: extracellular domain of CTLA-4 and Fc domain of human IgG1

BRIEFING DOCUMENT. human, recombinant fusion protein: extracellular domain of CTLA-4 and Fc domain of human IgG1 BRIEFING DOCUMENT Application Type BLA Submission Number 125118/0 Reviewer Name Team Leader Division Director Established Name (Proposed) Trade Name Applicant Formulation Dosing Regimen Indication Intended

More information

Supplementary appendix

Supplementary appendix Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Ruperto N, Martini A. Current and future perspectives

More information

James R. O Dell, M.D. University of Nebraska Medical Center

James R. O Dell, M.D. University of Nebraska Medical Center Not everyone in the world needs a biologic: Lessons from TEAR and RACAT James R. O Dell, M.D. University of Nebraska Medical Center Disclosure Declaration James O Dell, MD Advisory Board for Crescendo,

More information

UNFOLDING NATURE S ORIGAMI: MEDICAL TREATMENT OF TAKAYASU ARTERITIS AND GIANT CELL ARTERITIS

UNFOLDING NATURE S ORIGAMI: MEDICAL TREATMENT OF TAKAYASU ARTERITIS AND GIANT CELL ARTERITIS UNFOLDING NATURE S ORIGAMI: MEDICAL TREATMENT OF TAKAYASU ARTERITIS AND GIANT CELL ARTERITIS CanVasc meeting Montreal Nov 22 2012 Patrick Liang Service de rhumatologie Centre Hospitalier Universitaire

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT RoActemra 20 mg/ml concentrate for solution for infusion. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml concentrate contains

More information

Industry Relationships and Institutional Affiliations

Industry Relationships and Institutional Affiliations Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated daily statin: results from the ODYSSEY COMBO II study Christopher

More information

Design and Analysis of a Cancer Prevention Trial: Plans and Results. Matthew Somerville 09 November 2009

Design and Analysis of a Cancer Prevention Trial: Plans and Results. Matthew Somerville 09 November 2009 Design and Analysis of a Cancer Prevention Trial: Plans and Results Matthew Somerville 09 November 2009 Overview Objective: Review the planned analyses for a large prostate cancer prevention study and

More information

IL-6 Targeting. Arthur Kavanaugh: Disclosures. Abbott Amgen Astra-Zeneca Biogen-Idec BMS Celgene Centocor Genentech TREG Consultants LLC

IL-6 Targeting. Arthur Kavanaugh: Disclosures. Abbott Amgen Astra-Zeneca Biogen-Idec BMS Celgene Centocor Genentech TREG Consultants LLC IL-6 Targeting Arthur Kavanaugh, MD Professor of Medicine Division of Rheumatology, Allergy, and Immunology Director, Center for Innovative Therapy University of California San Diego La Jolla, CA Arthur

More information

Study Number CAIN457C2302 (core study) and CAIN457C2302E1 (extension study)

Study Number CAIN457C2302 (core study) and CAIN457C2302E1 (extension study) Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Secukinumab Therapeutic Area of Trial Uveitis Approved Indication Investigational Study Number CC2302 (core study) and CC2302E1

More information

Full Novartis CTRD Results Template

Full Novartis CTRD Results Template Full Novartis CTRD Results Template Sponsor Novartis Generic Drug Name vildagliptin Therapeutic Area of Trial Type 2 diabetes Approved Indication Type 2 diabetes Protocol Number CLAF237A23138E1 Title A

More information

London, 1 June 2006 Product name: REMICADE Procedure number: Remicade-H-240-II-73-AR SCIENTIFIC DISCUSSION 1/8

London, 1 June 2006 Product name: REMICADE Procedure number: Remicade-H-240-II-73-AR SCIENTIFIC DISCUSSION 1/8 London, 1 June 2006 Product name: REMICADE Procedure number: Remicade-H-240-II-73-AR SCIENTIFIC DISCUSSION 1/8 1. Introduction Infliximab is a chimeric human-murine IgG1κ monoclonal antibody, which binds

More information

Regulatory Status FDA-approved indication: Enbrel is a tumor necrosis factor (TNF) blocker indicated for the treatment of:

Regulatory Status FDA-approved indication: Enbrel is a tumor necrosis factor (TNF) blocker indicated for the treatment of: Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Section: Prescription Drugs Effective Date: Oct 1, 2016 Subject: Enbrel Page: 1 of 7 Last Review Date:

More information

American College of Rheumatology Analyst and Investor Meeting November 6, 2011

American College of Rheumatology Analyst and Investor Meeting November 6, 2011 American College of Rheumatology 2011 Analyst and Investor Meeting November 6, 2011 Chuck Triano Senior Vice President, Investor Relations Forward-Looking Statements Our discussions during this meeting

More information

TARGET Clinical Trial Identifier: NCT American College of Rheumatology Annual Meeting; November 7-11, 2015; San Francisco, CA

TARGET Clinical Trial Identifier: NCT American College of Rheumatology Annual Meeting; November 7-11, 2015; San Francisco, CA Efficacy and Safety of Sarilumab in Combination With csdmards in Patients With Active Rheumatoid Arthritis Who Were Inadequate Responders or Intolerant of Anti-TNF Therapy: Results From a Phase 3 Study

More information

University of Bristol - Explore Bristol Research. Peer reviewed version. Link to published version (if available): / X.

University of Bristol - Explore Bristol Research. Peer reviewed version. Link to published version (if available): / X. Sen, E. S., & Ramanan, A. V. (2016). Biologic drugs in pediatric rheumatology. International Journal of Rheumatic Diseases, 19(6), 533-535. https://doi.org/10.1111/1756-185x.12924 Peer reviewed version

More information

SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS DRUG

SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS DRUG SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS Anakinra Kineret 100mg/0.67mg pre-filled syringe For the treatment of systemic juvenile idiopathic arthritis in patients who meet the following criteria; Patient

More information

Saudi Arabia February Pr Michel KOMAJDA. Université Pierre et Marie Curie Hospital Pitié Salpétrière

Saudi Arabia February Pr Michel KOMAJDA. Université Pierre et Marie Curie Hospital Pitié Salpétrière Prevention of Cardiovascular events with Ivabradine: The SHIFT Study Saudi Arabia February 2011 Pr Michel KOMAJDA Université Pierre et Marie Curie Hospital Pitié Salpétrière Paris FRANCE Declaration Of

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis

More information

SYNOPSIS 2/198 CSR_BDY-EFC5825-EN-E02. Name of company: TABULAR FORMAT (For National Authority Use only)

SYNOPSIS 2/198 CSR_BDY-EFC5825-EN-E02. Name of company: TABULAR FORMAT (For National Authority Use only) SYNOPSIS Title of the study: A randomized, double-blind, placebo-controlled, parallel-group, fixed-dose (rimonabant 20 mg) multicenter study of long-term glycemic control with rimonabant in treatment-naïve

More information

Sponsor. Novartis Pharmaceuticals Corporation Generic Drug Name. Agomelatine Therapeutic Area of Trial. Major depressive disorder Approved Indication

Sponsor. Novartis Pharmaceuticals Corporation Generic Drug Name. Agomelatine Therapeutic Area of Trial. Major depressive disorder Approved Indication Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Corporation Generic Drug Name Therapeutic Area of Trial Major depressive disorder Approved Indication Investigational drug Study

More information

Extended report. Clinical and epidemiological research. Key messages

Extended report. Clinical and epidemiological research. Key messages Clinical and epidemiological research Handling editor Josef S Smolen Additional material is published online only. To view please visit the journal online (http:// dx. doi. org/ 10. 1136/ annrheumdis-

More information

Summary of Risk Minimization Measures

Summary of Risk Minimization Measures Table 6.1.4-1: Summary of Risk Minimization Measures Safety Concern Vaccination Hepatic and renal impairment Combination therapy Elderly Routine Risk Minimization Measures Specific subsection on vaccination

More information

WARNING: RISK OF SERIOUS INFECTIONS

WARNING: RISK OF SERIOUS INFECTIONS RA PROGRESSION INTERRUPTED 1 DOSAGE AND ADMINISTRATION GUIDE No structural damage progression was observed at week 52 in 55.6% and in 47.8% of patients receiving KEVZARA 200 mg + MTX or 150 mg + MTX, compared

More information

Monoclonal Antibodies in the Management of Rheumatoid Arthritis Prof. John D. Isaacs

Monoclonal Antibodies in the Management of Rheumatoid Arthritis Prof. John D. Isaacs John D Isaacs Professor of Clinical Rheumatology Director, Wilson Horne Immunotherapy Centre Newcastle University, UK 1 Rheumatoid arthritis Targeting T-cells Targeting B-cells Costimulation blockade Novel

More information

Horizon Scanning Technology Summary. Adalimumab (Humira) for juvenile idiopathic arthritis. National Horizon Scanning Centre.

Horizon Scanning Technology Summary. Adalimumab (Humira) for juvenile idiopathic arthritis. National Horizon Scanning Centre. Horizon Scanning Technology Summary National Horizon Scanning Centre Adalimumab (Humira) for juvenile idiopathic arthritis June 2007 This technology summary is based on information available at the time

More information

PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI

PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.

More information

Overview of Paediatric Investigation Plan (PIP) in Paediatric Rheumatology

Overview of Paediatric Investigation Plan (PIP) in Paediatric Rheumatology Overview of Paediatric Investigation Plan (PIP) in Paediatric Rheumatology Paediatric Rheumatology Expert Meeting, London 4 th December 29 Dr. Richard Veselý, Dr. Emma Sala Soriano Paediatric Investigation

More information

Pros and Cons of Combination MTX+ Biologics vs Monotherapy with Biologics: the place of immunogenicity

Pros and Cons of Combination MTX+ Biologics vs Monotherapy with Biologics: the place of immunogenicity Pros and Cons of Combination MTX+ Biologics vs Monotherapy with Biologics: the place of immunogenicity Daniel E Furst MD University of California in Los Angeles University of Washington University of Florence

More information

11/5/2011. Disclosures. Key References. JAK Inhibitors. Tofacitinib(CP ): Phase 2 Studies

11/5/2011. Disclosures. Key References. JAK Inhibitors. Tofacitinib(CP ): Phase 2 Studies Disclosures KINASE INHIBITORS IN RA Michael E. Weinblatt, M.D. Dr. Weinblatt has been a consultant to the following companies involved in the JAK and SYK pathways in RA Pfizer Vertex Astellas Rigel Astra-Zeneca

More information

THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI.

THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI. PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.

More information

24-Week CNTO1275PSA3001 Clinical Study Report

24-Week CNTO1275PSA3001 Clinical Study Report 24-Week CNTO1275PSA3001 Clinical Study Report SYNOPSIS Issue Date: 17 Jan 2013 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient(s) Janssen Research & Development, Inc Ustekinumab

More information

tocilizumab (Actemra )

tocilizumab (Actemra ) Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided

More information

EMA EFPIA workshop Break-out session no. 2

EMA EFPIA workshop Break-out session no. 2 EMA EFPIA workshop Break-out session no. 2 Case Study Title: Improvement of clinical benefit for a sub-group of pediatric systemic Juvenile Idiopathic Arthritis (sjia)) patients utilizing model-based dose

More information

The Use of Methotrexate in Juvenile Idiopathic Arthritis: A Single Center Experience

The Use of Methotrexate in Juvenile Idiopathic Arthritis: A Single Center Experience HK J Paediatr (new series) 2006;11:191-198 The Use of Methotrexate in Juvenile Idiopathic Arthritis: A Single Center Experience PPW LEE, TL LEE, WHS WONG, YL LAU Abstract Key words In the recent decade,

More information

SYNOPSIS. Issue Date: 25 Oct 2011

SYNOPSIS. Issue Date: 25 Oct 2011 SYNOPSIS Issue Date: 25 Oct 2011 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient(s) Janssen Research & Development STELARA Ustekinumab Protocol No.: Title of Study: Study Name:

More information

Sponsor / Company: sanofi-aventis and Proctor & Gamble Drug substance(s): Risedronate (HMR4003)

Sponsor / Company: sanofi-aventis and Proctor & Gamble Drug substance(s): Risedronate (HMR4003) These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: sanofi-aventis and

More information

ClinialTrials.gov Identifier: sanofi-aventis. Sponsor/company: 07/November/2008

ClinialTrials.gov Identifier: sanofi-aventis. Sponsor/company: 07/November/2008 These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinialTrials.gov

More information

ACTEMRA (tocilizumab)

ACTEMRA (tocilizumab) ACTEMRA (tocilizumab) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs

More information

1.0 Abstract. Title. Keywords. Adalimumab, Rheumatoid Arthritis, Effectiveness, Safety. Rationale and Background

1.0 Abstract. Title. Keywords. Adalimumab, Rheumatoid Arthritis, Effectiveness, Safety. Rationale and Background 1.0 Abstract Title Assessment of the safety of adalimumab in rheumatoid arthritis (RA) patients showing rapid progression of structural damage of the joints, who have no prior history of treatment with

More information

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

SYNOPSIS. International co-ordinating investigator Redacted

SYNOPSIS. International co-ordinating investigator Redacted Drug product: Drug substance(s): AZD6140 Document No.: D5130C00002 Edition No.: 01 Study code: D5130C00002 Date: 12 October 2005 SYNOPSIS A Double-blind, Double-dummy, Parallel Group Randomised Dose Confirmation

More information

New Evidence reports on presentations given at EULAR Rituximab for the Treatment of Rheumatoid Arthritis and Vasculitis

New Evidence reports on presentations given at EULAR Rituximab for the Treatment of Rheumatoid Arthritis and Vasculitis New Evidence reports on presentations given at EULAR 2011 Rituximab for the Treatment of Rheumatoid Arthritis and Vasculitis Report on EULAR 2011 presentations Anti-TNF failure and response to rituximab

More information

Discordance between physician s and parent s global assessments in juvenile idiopathic arthritis

Discordance between physician s and parent s global assessments in juvenile idiopathic arthritis Rheumatology 2007;46:141 145 Advance Access publication 16 June 2006 Discordance between physician s and parent s global assessments in juvenile idiopathic arthritis doi:10.1093/rheumatology/kel201 F.

More information

A.K. Gitt, F. Towae, C. Juenger, A. Papp, R. Zahn, U. Zeymer, J. Senges For the STAR-Study-Group Herzzentrum Ludwigshafen, Germany

A.K. Gitt, F. Towae, C. Juenger, A. Papp, R. Zahn, U. Zeymer, J. Senges For the STAR-Study-Group Herzzentrum Ludwigshafen, Germany Impact of Interventional Versus Conservative Approach on 5-Year-Mortality of Patients With Stable Angina and Documented Coronary Artery Disease in Clinical Practice: Results of the STAR-Registry A.K. Gitt,

More information

ENBREL (Etanercept) 25 mg and 50 mg powder for injection and water for injections

ENBREL (Etanercept) 25 mg and 50 mg powder for injection and water for injections PRODUCT INFORMATION ENBREL Etanercept (rch) NAME OF THE MEDICINE ENBREL (Etanercept) 25 mg and 50 mg powder for injection and water for injections ENBREL (Etanercept) 25 mg and 50 mg solution for injection

More information

ABSTRACT. Keywords: Africa; Efficacy; Etanercept; Maintenance therapy; Middle East; Rheumatoid arthritis ORIGINAL RESEARCH

ABSTRACT. Keywords: Africa; Efficacy; Etanercept; Maintenance therapy; Middle East; Rheumatoid arthritis ORIGINAL RESEARCH Rheumatol Ther (2018) 5:149 158 https://doi.org/10.1007/s40744-018-0094-6 ORIGINAL RESEARCH Maintenance of Remission with Etanercept DMARD Combination Therapy Compared with DMARDs Alone in African and

More information

U of Cape Town, South Africa, 10 U of Washington, Seattle, WA,USA, 11 CHRU de Lille, Hôpital Claude Huriez, Lille, France, 12

U of Cape Town, South Africa, 10 U of Washington, Seattle, WA,USA, 11 CHRU de Lille, Hôpital Claude Huriez, Lille, France, 12 A Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Ustekinumab, a Human IL-12/23p40 Monoclonal Antibody, in Moderate-severe Crohn s Disease Refractory to Anti-TNFα: UNITI-1 WJ Sandborn 1,

More information

ORENCIA (abatacept) Demonstrates Comparable Efficacy to Humira ( adalimumab

ORENCIA (abatacept) Demonstrates Comparable Efficacy to Humira ( adalimumab ORENCIA (abatacept) Demonstrates Comparable Efficacy to Humira (adalimumab) in Patients with Moderate to Severe Rheumatoid Arthritis in First Head-to-Head Study of These Agents ORENCIA demonstrated comparable

More information

Ethnic Minority RA Consortium (EMRAC)

Ethnic Minority RA Consortium (EMRAC) Ethnic Minority RA Consortium (EMRAC) Yusuf Yazıcı, MD Assistant Professor of Medicine, New York University School of Medicine Director, Seligman Center for Advanced Therapeutics & Behçet Syndrome Evaluation,

More information

Adalimumab M Clinical Study Report Final R&D/13/224

Adalimumab M Clinical Study Report Final R&D/13/224 Diagnosis and Main Criteria for Inclusion: A parent or guardian had voluntarily signed and dated an informed consent form, approved by an institutional review board/independent ethics committee, after

More information

Use of tocilizumab in Juvenile Idiopathic Arthritis

Use of tocilizumab in Juvenile Idiopathic Arthritis S54 Use of tocilizumab in Juvenile Idiopathic Arthritis Evidence Based Medicine Official recommendations Expert opinion The data generated by clinical trials of tocilizumab in adults with rheumatoid arthritis

More information

THE USE OF BIOLOGICS RESPONSE MODIFIERS IN POLYARTICULAR- COURSE JUVENILE IDIOPATHIC ARTHRITIS

THE USE OF BIOLOGICS RESPONSE MODIFIERS IN POLYARTICULAR- COURSE JUVENILE IDIOPATHIC ARTHRITIS The Hospital for Sick Children Technology Assessment at Sick Kids (TASK) THE USE OF BIOLOGICS RESPONSE MODIFIERS IN POLYARTICULAR- COURSE JUVENILE IDIOPATHIC ARTHRITIS Authors: Vania Costa, MSc Research

More information

Safety, effectiveness, and pharmacokinetics of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to 4 years

Safety, effectiveness, and pharmacokinetics of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to 4 years Clin Rheumatol (2014) 33:1433 1441 DOI 10.1007/s10067-014-2498-1 ORIGINAL ARTICLE Safety, effectiveness, and pharmacokinetics of adalimumab in children with polyarticular juvenile idiopathic arthritis

More information

ClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt Release Date: 01/19/2016. ClinicalTrials.gov ID: NCT

ClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt Release Date: 01/19/2016. ClinicalTrials.gov ID: NCT ClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt Release Date: 01/19/2016 ClinicalTrials.gov ID: NCT00595413 Study Identification Unique Protocol ID: 27905 Brief Title: Atacicept

More information

Pediatric rheumatic diseases (PRDs) are rare

Pediatric rheumatic diseases (PRDs) are rare World Journal of Pediatrics Network in pediatric rheumatology: the example of the Pediatric Rheumatology International Trials Organization Nicolino Ruperto, Alberto Martini Genova, Italy 186 Background:

More information

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information